Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy
- PMID: 30558908
- DOI: 10.1016/S2213-8587(18)30321-8
Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy
Comment on
-
Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.Lancet Diabetes Endocrinol. 2019 Feb;7(2):93-105. doi: 10.1016/S2213-8587(18)30307-3. Epub 2018 Dec 14. Lancet Diabetes Endocrinol. 2019. PMID: 30558909 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
